Chronic Obstructive Pulmonary Disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care

Thorax

Volumn 59, Issue SUPPL. 1, 2004, Pages 1-232

  Pearson, Mike ^a  

^a Natl Collaborating Ctr Chron C   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILOMILAST; CORTICOSTEROID; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUTICASONE; FLUTICASONE PROPIONATE; FORMOTEROL; INFLUENZA VACCINE; IPRATROPIUM BROMIDE; ISOPRENALINE; NIFEDIPINE; ORCIPRENALINE; OXYGEN; PHOSPHODIESTERASE IV INHIBITOR; PNEUMOCOCCUS VACCINE; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG;

ANXIETY DISORDER; ASSISTED VENTILATION; ASTHMA; BONE FRAGILITY; CANDIDIASIS; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COR PULMONALE; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DISEASE SEVERITY; EARLY DIAGNOSIS; ECONOMIC ASPECT; FOLLOW UP; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HUMAN; INFLUENZA; INFLUENZA VACCINATION; LUNG RESECTION; LUNG TRANSPLANTATION; MEDICAL NEBULIZER; META ANALYSIS; METERED DOSE INHALER; MORBIDITY; MORTALITY; NAUSEA; NICOTINE REPLACEMENT THERAPY; OCCUPATIONAL THERAPY; OROPHARYNX; OROPHARYNX CANDIDIASIS; OXYGEN THERAPY; PALLIATIVE THERAPY; PATIENT EDUCATION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN BRUISING; SMOKING CESSATION; SPIROMETRY; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; THRUSH; TREATMENT OUTCOME;

ADULT; ALGORITHMS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; GREAT BRITAIN; HEALTH POLICY; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STATE MEDICINE;

EID: 1542405163     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (491)

1. Cox, B. D. Blood pressure and respiratory function 1987. In: The health and lifestyle survey. Preliminary report of a nationwide survey of the physical and mental health, attitudes and lifestyle of a random sample of 9003 British adults. Health Promotion Research Trust, 17-33. London. Ref ID: 19416
2. Renwick, D. S. and Connolly, M. J. Prevalence and treatment of chronic airways obstruction in adults over the age of 45. Thorax. 1996; 51(2): 164-168. Ref ID: 19450
3. Seamark DA, Williams S, Timon S, Ward A, Ward D, Seamark C et al. Home or surgery based screening for chronic obstructive pulmonary disease (COPD)? Primary Care Respiratory Journal 2001;10:30-3. Ref ID: 1184
4. Pride NB, Soriano JB. Chronic obstructive pulmonary disease in the United Kingdom: trends in mortality, morbidity and smoking. Current Opinion in Pulmonary Medicine 2002;8:95-101. Ref ID: 19417
5. Office for National Statistics. Health Statistics Quarterly. 8. 2000. London, HMSO. Ref ID: 19418
6. Soriano JB, Maier WC, Egger P, Visick G, Thakrar B, Sykes J et al. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 2000;55:789-94. Ref ID: 105
7. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000;160:1683-9. Ref ID: 19246
8. Office for National Statistics. Mortality statistics: Cause, 1999. DH2 (No 26). 2000. London. HMSO. Ref ID: 19419
9. Office for National Statistics. Living in London. Results from the 1998 General Household Survey. 2000. London. HMSO Ref ID: 19420
10. Damiani M. Dixon J. Managing the pressure. Emergency hospital admissions in London 1997-2001. 2002. London. Kings Fund. Ref ID: 19421
11. Anderson, R. H., Esmail, A., and Hollowell, J. Epidemiologically based needs assessment: Report 16: lower respiratory disease. 2003. London, Department of Health. Ref ID: 19422
12. Office of Population Census and Surveys. Morbidity Statistics from General Practice. Fourth national study 1991-1992. 1995. London, HMSO. Ref ID: 19423
13. Britton M. The burden of COPD in the U.K.: results from the Confronting COPD survey. Respir Med 2003;97 Suppl C:S71-S79. Ref ID: 19251
14. Eccles, M. and Mason, J. How to develop cost-conscious guidelines. Health Technology Assessment. Vol. 5. 16: 1-69. 2001. Ref ID: 19424
15. National Institute for Clinical Excellence. Information for National Collaborating Centres and Guideline Development Groups. 2001. The Guideline Development Process series No 3. 2001. London. National Institute for Clinical Excellence. Ref ID: 2038
16. Scottish Intercollegiate Guidelines Network. SIGN 50 A guideline developers' handbook. 2001. SIGN. Ref ID: 19457
17. Murphy, M. K., Black, N. A., Lamping, D. L., McKee, C. M., Sanderson, C. F., and Askham, J. et al. Consensus development methods, and their use in clinical guideline development. Health Technology Assessment. Vol. 2. 1998. Ref ID: 19425
18. National Institute for Clinical Excellence. Information for National Collaborating Centres and Guideline Development Groups. The Guideline Development Process Series No. 3., 1-65. 2003. London. National Institute for Clinical Excellence. Ref ID: 19426
19. Fletcher CM, Elmes PC, Fairbairn MB, Wood CH. The Significance of Respiratory Symptoms and the Diagnosis of Chronic Bronchitis in a Working Population. British Medical Journal 1959;2:257-66. Ref ID: 1269
20. Quanjer PH, Tammeling GJ, Cotes JE, Pederson OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5-40. Ref ID: 19247
21. Nolan D, White P, Pearson MG. FEV-1 and PEF in COPD management. Thorax 1999;54:468-9. Ref ID: 12121
22. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001;56:880-7. Ref ID: 8033
23. Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986;133:14-20. Ref ID: 628
24. Burrows B. The course and prognosis of different types of chronic airflow limitation in a general population sample from Arizona: comparison with the Chicago "COPD" series. Am Rev Respir Dis 1989;140:S92-S94. Ref ID: 2373
25. COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997;52:S11-28. Ref ID: 3490
26. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. 2001. Ref ID: 54
27. British Thoracic Society, Scottish Intercollegiate Guideline Network. British Guideline on the management of asthma. Thorax 2003;58:1-94. Ref ID: 19459
28. Calverley PMA, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003;58:659-64. Ref ID: 19248
29. Anthonisen NR, Wright EC. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986;133:814-9. Ref ID: 626
30. Nisar M, Walshaw M, Earis JE, Pearson MG, Calverley PM. Assessment of reversibility of airway obstruction in patients with chronic obstructive airways disease. Thorax 1990;45:190-4. Ref ID: 1212
31. Nisar M, Earis JE, Pearson MG, Calverley PM. Acute bronchodilator trials in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992;146:555-9. Ref ID: 12080
32. Hadcroft J, Calverley PM. Alternative methods for assessing bronchodilator reversibility in chronic obstructive pulmonary disease. Thorax 2001;56:713-20. Ref ID: 6526
33. Brand PL, Quanjer PH, Postma DS, Kerstjens HA, Koeter GH, Dekhuijzen PN et al. Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group. Thorax 1992;47:429-36. Ref ID: 2009
34. Tweeddale PM, Alexander F, Mchardy GJR. Short-term variability in fev1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax 1987;42:487-90. Ref ID: 1221
35. Fabbri, L. M., Romagnoli, M., Corbetta, L., Casoni, G., Busljetic, K., and Turato, G. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Journal of Respiratory Critical Care Medicine 167(3), 418-424. 2003. Ref ID: 19478
36. Santus P, Pecchiari M, Carlucci P, Boveri B, Di Marco F, Castagna F et al. Bronchodilation test in COPD: effect of inspiratory manoeuvre preceding forced expiration. European Respiratory Journal. 2003;21:82-5. Ref ID: 19479
37. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax 2003;58:1-5. Ref ID: 1791
38. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256-76. Ref ID: 12738
39. Freeman D. COPD prevalence in asymptomatic smokers - The first 100. Prim Care Respir J 2000;9:41. Ref ID: 5414
40. van Schayck CP, Loozen JM, Wagena E, Akkermans RP, Wesseling GJ. Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. BMJ 2002;324:1370-4. Ref ID: 19249
41. Humerfelt S, Eide G, Aaro L, Gulsvik A. Effectiveness of postal smoking cessation advice: a randomised controlled trial in young men with reduced FEV1 and asbestos exposure. Eur Respir J 1998;11:284-90. Ref ID: 1285
42. Risser NL, Belcher DW. Adding spirometry, carbon-monoxide, and pulmonary symptom results to smoking cessation counseling - a randomized trial. Journal of General Internal Medicine 1990;5:16-22. Ref ID: 1241
43. Jonsson JS, Gislason T, Gislason D, Sigurdsson JA. Acute bronchitis and clinical outcome three years later: prospective cohort study. BMJ 1998;317:1433. Ref ID: 8066
44. BTS. BTS guidelines for the management of COPD. The COPD Guielines Group of the Standards of Care Committee of the BTS. Thorax 52(Suppl 5), S1-28. 1997. Ref ID: 57
45. van der Meer RM, Wagena EJ, Ostelo RWJG, Jacobs JE, van Schayck CP. Smoking cessation for chronic obstructive pulmonary disease. (Cochrane Review). The Cochrane Library.Oxford:Update Software 2003;Issue 3. Ref ID: 19361
46. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272:1497-505. Ref ID: 998
47. Brandt CJ, Ellegaard H, Joensen M, Kallan FV, Sorknaes AD, Tougaard L. Effect of diagnosis of "smoker's lung". RYLUNG Group. Lancet 1997;349:253. Ref ID: 984
48. Crowley TJ, Macdonald MJ, Walter MI. Behavioral anti-smoking trial in chronic obstructive pulmonary disease patients. Psychopharmacology 1995;119:193-204. Ref ID: 992
49. Pederson LL, Wanklin JM, Lefcoe NM. The effects of counseling on smoking cessation among patients hospitalized with chronic obstructive pulmonary disease: a randomized clinical trial. International Journal of the Addictions 1991;26:107-19. Ref ID: 1010
50. Tashkin, D., Kanner, R., Bailey, W. et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001;357:1571-5. Ref ID: 977
51. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease - The Lung Health Study. American Journal of Respiratory and Critical Care Medicine 2000;161:381-90. Ref ID: 166
52. Kanner RE, Connett JE, Williams DE, Buist AS. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. American Journal of Medicine 1999;106:410-6. Ref ID: 979
53. National Institute for Clinical Excellence. Guidance on the use of Nicotine Replacement Therapy (NRT) and bupropion for smoking cessation. NICE Technology Appraisal Guidance No 39. 2002. London. National Institute for Clinical Excellence. Ref ID: 1150
54. Woolacott, N. F., Jones, L., Forbes, C. A., Mather, L. C., Sowden, A. J., Song, F. J., Raftery, J. P., Aveyard, P. N., Hyde, C. J., and Barton, P. M. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technology Assessment 6(16), 1-245. 2002. Ref ID: 19250
55. Corris PA, Neville E, Narimans, Gibson GJ. Dose-response study of inhaled salbutamol powder in chronic air-flow obstruction. Thorax 1983;38:292-6. Ref ID: 170
56. Teale C, Morrison JFJ, Page RL, Pearson SB. Dose-response to inhaled salbutamol in chronic obstructive airways disease. Postgraduate Medical Journal 1991;67:754-6. Ref ID: 183
57. Sestini P, Renzoni E, Robinson S, Poole P, Ram F.S.F. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. The Cochrane Library.Oxford:Update Software 2003; Issue 3. Ref ID: 819
58. Dullinger D, Kronenberg R, Niewoehner DE. Efficacy of inhaled metaproterenol and orally-administered theophylline in patients with chronic airflow obstruction. Chest. 1986;89:171-3. Ref ID: 317
59. Guyatt GH, Townsend M, Pugsley SO, Keller JL, Short HD, Taylor DW et al. Bronchodilators in chronic air-flow limitation. Effects of airway function, exercise capacity, and quality of life. American Review of Respiratory Disease 1987;135:1069-74. Ref ID: 575
60. Guyatt GH, Townsend M, Nogradi S, Pugsley SO, Keller JL, Newhouse MT. Acute response to bronchodilator. An imperfect guide for bronchodilator therapy in chronic airflow limitation. Archives of Internal Medicine 1988;148:1949-52. Ref ID: 1760
61. Guyatt GH, Townsend M, Keller IL, Singer J. Should study subjects see their previous responses: data from a randomized control trial. Journal of Clinical Epidemiology 1989;42:913-20. Ref ID: 521
62. Hansen NC, May O. Domiciliary nebulised terbutaline in severe chronic airways obstruction. European Respiratory Journal 1990;3:463-4. Ref ID: 19429
63. Jaeschke R, Guyatt GH, Singer J, Keller J, Newhouse MT. Mechanism of bronchodilator effect in chronic airflow limitation. Canadian Medical Association Journal 1991;144:35-9. Ref ID: 19427
64. Klock LE, Miller TD, Morris AH, Watanabe S, Dickman MA. A comparative study of atropine sulphate and isoproterenol hydrochloride in chronic bronchitis. American Review of Respiratory Disease 1975;112:371-6. Ref ID: 19430
65. Light RW, Summer WR, Luchsinger PC. Response of patients with chronic obstructive lung disease to the regular administraion of nebulised isoproterenol. Chest 1975;67:634-9. Ref ID: 19431
66. Shah SS, Johnsonton D, Woodcock AA, Johnson M, Geddes DM. Breathlessness and exercise tolerance in chronic airflow obstruction: 2-hourly versus 4-hourly salbutamol by inhalation. Current Medical Research and Opinion 1983;8:345-9. Ref ID: 19432
67. Silins RA, Marlin GE. Evaluation of domiciliary treament with terbutaline by wet nebulisation in patients with chronic bronchitis and emphysema. Australian and New Zealand Journal of Medicine 1985;15:230-40. Ref ID: 19433
68. Tandon MK, Kailis SG. Bronchodilator treatment for partially reversible chronic obstructive airways disease. Thorax 1991;46:248-51. Ref ID: 496
69. Taylor DR, Buick B, Kinney C. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. American Review of Respiratory Disease 1985;131:747-51. Ref ID: 657
70. Wilson RSE, Connellan SJ. Domiciliary nebulized salbutamol solution in severe chronic airway obstruction in severe chronic airway obstruction. Thorax 1980;35:873-6. Ref ID: 846
71. Cook D, Guyatt G, Wong E, Goldstein R, Bedard M, Austin P et al. Regular versus as-needed short-acting inhaled beta-agonist therapy for chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine 2001;163:85-90. Ref ID: 129
72. Gross NJ, Co E, Skorodin MS. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest 1989;96:984-7. Ref ID: 6307
73. Ikeda A, Nishimura K, Koyama H, Izumi T. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable copd - comparison with ipratropium bromide alone. Chest 1995;107:401-5. Ref ID: 188
74. Keda A, Nishimura K, Koyama H, Izumi T. Comparative dose-response study of 3 anticholinergic agents and fenoterol using a metered-dose inhaler in patients with chronic obstructive pulmonary-disease. Thorax 1995;50:62-6. Ref ID: 157
75. Higgins BG, Powell RM, Cooper S, Tattersfield AE. Effect of salbutamol and ipratropium bromide on airway caliber and bronchial reactivity in asthma and chronic-bronchitis. European Respiratory Journal 1991;4:415-20. Ref ID: 150
76. Braun SR, Mckenzie WN, Copeland C, Knight L, Ellerseick M. A comparison of the effect of ipratropium and albuterol in the treatment of chronic obstructive airway disease. Archives of Internal Medicine 1989;149:544-7. Ref ID: 545
77. Campbell S. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Archives of Internal Medicine. 1999. 159(2):156-60. Ref ID: 826
78. Colice GL. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease. American Journal of Medicine. 1996;100(1):11-18. Ref ID: 326
79. Rennard SI, Serby CW, Ghafouri M, Johnson PA, Friedman M. Extended therapy with ipratropium is associated with improved lung function in patients with COPD: A retrospective analysis of data from seven clinical trials. Chest 1996;110:62-70. Ref ID: 301
80. Taylor J, Kotch A, Rice K, Ghafouri M, Kurland CL, Fagan NA et al. Ipratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in patients with COPD. Chest 2001;120:1253-61. Ref ID: 156
81. Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M et al. Use of a long-acting inhaled beta(2)-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2001;163:1087-92. Ref ID: 173
82. Dahl R, Greefhorst LAPM, Nowak D, Nonikov V, Byrne AM, Thomson MH et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2001;164:778-84. Ref ID: 171
83. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957-65. Ref ID: 37
84. Appleton S, Smith B, Veale A, Bara A. Long-acting beta2-agonists for chronic obstructive pulmonary disease.(Cochrane Review). The Cochrane Library.Oxford:Update Software 2003; Issue 3. Ref ID: 1137
85. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). [erratum appears in Eur Respir J 1997 Jul;10(7):1696.]. European Respiratory Journal 1997;10:815-21. Ref ID: 252
86. Goodwin, B., Cox, F., Anderson, W., Wisniewski, M., and Rickard, K. Comparision of salmeterol 42ug BID (SLG) versus ipratropium bromide 36ug q.i.d. vs placebo on disease specific quality of life in COPD patients: reversible or non-reversible to ventolin. ALA/ATS Abstract 1997-1999 . 1997. Ref ID: 19475
87. Grove A, Lipworth BJ, Reid P, Smith RP, Ramage L, Ingram CG et al. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax 1996;51:689-93. Ref ID: 265
88. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. American Journal of Respiratory and Critical Care Medicine 1997;155:1283-9. Ref ID: 180
89. Rutten-Van M, Roos B, van N. An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. Thorax. 1999;54:995-1003. Ref ID: 968
90. Ulrik CS. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study. Thorax 1995;50:750-4. Ref ID: 278
91. van Noord JA, de Munck DRAJ, Bantje TA, Hop WCJ, Akveld MLM, Bommer AL. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. European Respiratory Journal 2000;15:878-85. Ref ID: 175
92. Shukla, V. K., Husereau, D. R., Boucher, M., Mensunkai, S., and Dales, R. Long-acting beta2-agonists for maintenance therapy of stable chronic obstructive pulmonary disease: a systematic review. 39. 2002. Ottawa, Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Ref ID: 1764
93. Aalbers R, Ayres J, Backer V, Decramer M, Lier PA, Magyar P et al. Formoterol in patients with chronic obstructive pulmonary disease: A randomized, controlled, 3-month trial. European Respiratory Journal 2002;19:936-43. Ref ID: 249
94. Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002;121:1058-69. Ref ID: 966
95. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58:399-404. Ref ID: 1790
96. Mahler DA, Wire P, Horstman D, Chang C-N, Yates J, Fischer T et al Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine 2002;166:1084-91. Ref ID: 1689
97. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. [Erratum in Eur Respir J 2003;21:912]. European Respiratory Journal 2003;21:74-81. Ref ID: 1698
98. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 2003;361:449-56. Ref ID: 1702
99. Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122:47-55. Ref ID: 137
100. Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2000;161:1136-42. Ref ID: 176
101. Casaburi R, Briggs DD, Donohue JF, Serby CW, Menjoge SS, Witek TJ. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD - A 13-week multicenter trial. Chest 2000;118:1294-302. Ref ID: 174
102. Casaburi R, Mahler DA, Jones PW, Wanner A, San Pedro G, ZuWallack RL et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. European Respiratory Journal 2002;19:217-24. Ref ID: 34
103. Vincken W, van Noord JA, Greefhorst APM, Bantje TA, Kesten S, Korducki L et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. European Respiratory Journal 2002;19:209-16. Ref ID: 33
104. Vassallo R, Lipsky JJ. Theophylline: recent advances in the understanding o fits mode of action and uses in clinical practice. Mayo Clinic Proceedings 1998;73:346-54. Ref ID: 19434
105. Murciano D, Aubier M, Lecocguic Y, Pariente R. Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease. N Engl J Med 1984;311:349-53. Ref ID: 19435
106. Ziment I. Theophylline and mucociliary clearance. Chest 1987;92:38S-43S. Ref ID: 19436
107. Matthay RA, Mahler DA. Theophylline improves global cardiac function and reduces dyspnea in chronic obstructive lung disease. Journal of Allergy & Clinical Immunology 1986;78:793-9. Ref ID: 1758
108. Upton RA. Pharmacokinetic interactions between theophylline and other medication. Clin Pharmacokinet 1991;20:66-80. Ref ID: 19437
109. Aronson JK, Hardman M, Reynolds DJ. ABC of monitoring drug therapy. Theophylline. BMJ 1992;305:1355-8. Ref ID: 708
110. Ram FSF, Jones PW, Castro AA, De Brito JA, Atallah AN, Lacasse Y et al. Oral theophylline for chronic obstructive pulmonary disease. (Cochrane Review). The Cochrane Library.Oxford:Update Software 2003;Issue 3. Ref ID: 1713
111. Fink G, Kaye C, Sulkes J, Gabbay U, Spitzer SA. Effect of theophylline on exercise performance in patients with severe chronic obstructive pulmonary disease. Thorax. 1994;49:332-4. Ref ID: 1737
112. Newman D, Tamir J, Speedy L, Newman JP, Ben Dov I. Physiological and neuropsychological effects of theophylline in chronic obstructive pulmonary disease. Israel Journal of Medical Sciences 1994;30:811-6. Ref ID: 1748
113. Alexander MR, Dull WL, Kasik JE. Treatment of chronic obstructive pulmonary disease with orally administered theophylline. A double-blind, controlled study. Journal of the American Medical Association 1980;244:2286-90. Ref ID: 1731
114. Mulloy E, McNicholas WT. Theophylline improves gas exchange during rest, exercise, and sleep in severe chronic obstructive pulmonary disease. American Review of Respiratory Disease 1993;148:1030-6. Ref ID: 1745
115. Compton CH, Gubb J, Nieman R, Edelson J, Amit O, Bakst A et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 2001;358:265-70. Ref ID: 1261
116. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:542-8. Ref ID: 8391
117. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002;165:1592-6. Ref ID: 6796
118. Peperell K, Rudolf M, Pearson M, Diggle J. General practitioner prescribing habits in asthma/COPD. Asthma in General Practice 1997;5:29-30. Ref ID: 19287
119. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: A systematic review of randomized placebo-controlled trials. American Journal of Medicine 2002;113:59-65. Ref ID: 1668
120. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. British Medical Journal 2000;320:1297-303. Ref ID: 194
121. The Lung Health Study Research Group, Altose MD, Redline S, Deitz CD, Quinlan KJ, Eichenhorn MS et al. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. New England Journal of Medicine 2000;343:1902-9. Ref ID: 193
122. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-23. Ref ID: 196
123. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. New England Journal of Medicine 1999;340:1948-53. Ref ID: 195
124. van Grunsven PM, van Schayck CP, Derenne JP, Kerstjens HA, Renkema TE, Postma DS et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax 1999;54:7-14. Ref ID: 879
125. Derenne, J. P. Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 year prospective multicentre study. Am J Respir Crit Care Med 151. 1995. Ref ID: 19463
126. Johnell O, Pauwels R, Lofdahl C-G, Laitininen LA, Postma DS, Pride NB et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. European Respiratory Journal 2002;19:1058-63. Ref ID: 1711
127. Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003;21:68-73. Ref ID: 1787
128. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. European Respiratory Journal 2002;20:819-25. Ref ID: 1265
129. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:580-4. Ref ID: 19458
130. Sin DD, Man SFP. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: Does the dose matter? European Respiratory Journal 2003;21:260-6. Ref ID: 19360
131. Renkema, T. E., Scheuten, J. P., Koeter, G. H., and Postma, D. S. Effects of long-term treatment with corticosteroids in COPD. Chest 109, 1156-1162. 1996. Ref ID: 19474
132. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998;351:773-80. Ref ID: 197
133. Dragonetti ME, Groth ML. Inhaled cortiocsteroids in chronic obstructive pulmonary disease: Are they cost-effect? Clinical-Pulmonary-Medicine 2000;7. Ref ID: 19314
134. Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis. Annals of Internal Medicine 1991;114:216-23. Ref ID: 99
135. Corden Z, Rees PJ. The effect of oral corticosteroids on bronchodilator responses in COPD. Respiratory Medicine 1998;92:279-82. Ref ID: 1672
136. Weiner P, Weiner M, Rabner M, Waizman J, Magadle R, Zamir D. The response to inhaled and oral steroids in patients with stable chronic obstructive pulmonary disease. Journal of Internal Medicine 1999;245:83-9. Ref ID: 1709
137. Weir DC, Robertson AS, Gove RI, Burge PS. Time course of response to oral and inhaled corticosteroids in nonasthmatic chronic air-flow obstruction. Thorax 1990;45:118-21. Ref ID: 12
138. Weir DC, Gove RI, Robertson AS, Burge PS. Corticosteroid trials in non-asthmatic chronic airflow obstruction: A comparison of oral prednisolone and inhaled beclomethasone dipropionate. Thorax 1990;45:112-7. Ref ID: 1710
139. Royal College of Physicians. Osteoporosis. Clinical guidelines for prevention and treatment. 1999. London. Royal College Physicians. Ref ID: 19496
140. Chapman, Arvidsson PC. The addition of salmeterol 50 mg bid to anticholinergic treatment in patients with COPD: A randomized, placebo controlled trial. Canadian Respiratory Journal 2002;9:178-85. Ref ID: 1719
141. Auerbach D, Hill C, Baughman R, Boyars M, Braun S, Buist AS et al. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997;112:1514-21. Ref ID: 830
142. Bone R, Boyars M, Braun SR, Buist S, Campbell S, Chick T et al. In chronic obstructive pulmonary-disease, a combination of ipratropium and albuterol is more effective than either agent alone - an 85-day multicenter trial. Chest 1994;105:1411-9. Ref ID: 182
143. Gross N, Tashkin D, Miller R, Oren J, Coleman W, Linberg S et al. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Respiration 1998;65:354-62. Ref ID: 827
144. D'Urzo AD, De S, Ramirez-Rivera A, Almeida J, Sichletidis L, Rapatz G et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study. Chest 2001;119:1347-56. Ref ID: 973
145. Friedman M, Serby CW, Menjoge SS, Wilson JD, Hilleman DE, Witek TJ, Jr. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest. 1999;115:635-41. Ref ID: 1720
146. ZuWallack RL, Mahler DA, Reilly D, Church N, Emmett A, Rickard K et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001;119:1661-70. Ref ID: 1118
147. Bellia V, Foresi A, Bianco S, Grassi V, Olivieri D, Bensi G et al. Efficacy and safety of oxitropium bromide, theophylline and their combination in COPD patients: a double-blind, randomized, multicentre study (BREATH Trial). Respiratory Medicine 2002;96:881-9. Ref ID: 1264
148. Nishimura K, Koyama H, Ikeda A, Sugiura N, Kawakatsu K, Izumi T. The additive effect of theophylline on a high-dose combination of inhaled salbutamol and ipratropium bromide in stable COPD. Chest. 1995;107:718-23. Ref ID: 1722
149. Brocklebank, D. M, Ram, F. S. F, Wright, J., Barry, P., Cates, C., and Davies, L. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technology Assessment 5(26). 2001. Ref ID: 1374
150. Ram FSF, Brocklebank DM, Muers M, Wright J, Jones PW. Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease.(Cochrane Review). The Cochrane Library.Oxford:Update Software 2003;Issue 3. Ref ID: 1375
151. Cuvelier A, Muir J, Benhamou D, Guerin J, Weitzenblum E, Zuck P et al. Dry powder ipratropium bromide is as safe and effective as metered-dose inhaler formulation: a cumulative dose-response study in chronic obstructive pulmonary disease patients. Respiratory Care 2002;47:159-66. Ref ID: 1428
152. Eiser N, Angus K, McHale S. The role of domiciliary nebulizers in managing patients with severe COPD. Respiratory Medicine. 2001;95:265-74. Ref ID: 1429
153. O'Driscoll BR, Kay EA, Taylor RJ, Weatherby H, Chetty MCP, Bernstien A. A long-term prospective assessment of home nebulizer treatment. Respiratory Medicine 1992;86:317-25. Ref ID: 1432
154. Allen SC. Competence thresholds for the use of inhalers in people with dementia Age Ageing 1997;26:83-6. Ref ID: 19257
155. Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing 1972;1:233-8. Ref ID: 19255
156. Connolly MJ. Inhaler technique of elderly patients: comparison of metered-dose inhalers and large volume spacer devices. Age and Ageing 1995;24:190-2. Ref ID: 3396
157. Allen SC, Prior A. What determines whether an elderly patient can use a metered dose inhaler correctly? Br J Dis Chest 1986;80:45-9. Ref ID: 19258
158. Armitage JM, Williams SJ. Inhaler technique in the elderly. Age Ageing 1988;17:275-8. Ref ID: 19259
159. Selroos O, Halme M. Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler. Thorax 1991;46:891-4. Ref ID: 19261
160. Diggory P, Bailey R, Vallon A. Effectiveness of inhaled bronchodilator delivery systems for elderly patients. Age Ageing 1991;20:379-82. Ref ID: 19263
161. Harvey J, Williams JG. Randomised cross-over comparison of five inhaler systems for bronchodilator therapy. Br J Clin Pract 1992;46:249-51. Ref ID: 19262
162. Allen SC, Ragab S. Ability to learn inhaler technique in relation to cognitive scores and tests of praxis in old age. Postgrad Med J 2002;78:37-9. Ref ID: 19256
163. Teale C, Jones A, Patterson CJ, Kearney MT, Stanners AJ, Muers MF. Community survey of home nebulizer technique by elderly people. Age Ageing 1995;24:276-7. Ref ID: 16642
164. O'Driscoll BR. Nebulisers for chronic obstructive pulmonary disease. Thorax 1997;52:S49-S52. Ref ID: 87
165. Boe J, Dennis JH, O'Driscoll BR, Bauer TT, Carone M, Dautzenberg B et al. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J 2001;18:228-42. Ref ID: 19264
166. Formgren H, Sjokvist A, Stahl E, Wiren JE. Terbutaline in COPD comparison between Turbuhaler and chlorofluorocarbon (CFC) inhaler. Lung 1994;172:271-80. Ref ID: 1795
167. Ikeda A, Nishimura K, Koyama H, Tsukino M, Hajiro T, Mishima M et al. Comparison of the bronchodilator effects of salbutamol delivered via a metered-dose inhaler with spacer, a dry-powder inhaler, and a jet nebulizer in patients with chronic obstructive pulmonary disease. Respiration. 1999;66:119-23. Ref ID: 1440
168. Iacono P, Velicitat P, Guemas E, Leclerc V, Thebault JJ. Improved delivery of ipratropium bromide using Respimat (a new soft mist inhaler) compared with a conventional metered dose inhaler: cumulative dose response study in patients with COPD. Respiratory Medicine. 2000;94:490-5. Ref ID: 1439
169. Royal College of Physicians. Domiciliary oxygen therapy services. Clinical guidelines and advice for prescribers. London: Royal College of Physicians, 1999. Ref ID: 19265
170. Crockett AJ, Cranston JM, Moss JR, Alpers JH. Domiciliary oxygen for chronic obstructive pulmonary disease. (Cochrane Review). The Cochrane Library.Oxford:Update Software 2003;Issue 3. Ref ID: 1799
171. Ram FSF, Wedzicha JA. Ambulatory oxygen for chronic obstructive pulmonary disease. (Cochrane Review). The Cochrane Library.Oxford:Update Software 2003;Issue 3. Ref ID: 1796
172. Medical Research Council Working Party, Flenely DC. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981;1:681-6. Ref ID: 10882
173. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980;93:391-8. Ref ID: 12109
174. Timms RM, Khaja FU, Williams GW. Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. Ann Intern Med 1985;102:29-36. Ref ID: 16841
175. Cooper CB, Waterhouse J, Howard P. Twelve year clinical study of patients with hypoxic cor pulmonale given long term domiciliary oxygen therapy. Thorax 1987;42:105-10. Ref ID: 3471
176. Cooper CB, Howard P. An analysis of sequential physiologic changes in hypoxic cor pulmonale during long-term oxygen therapy. Chest 1991;100:76-80. Ref ID: 19266
177. Zielinski J, MacNee W, Wedzicha J, Ambrosino N, Braghiroli A, Dolensky J et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis 1997;52:43-7. Ref ID: 19267
178. PPA. Drug Tariff National Health Service, England and Wales. The Stationary Office Books, 2003. Ref ID: 19494
179. Heaney LG, McAllister D, MacMahon J. Cost minimisation analysis of provision of oxygen at home: are the drug tariff guidelines cost effective? BMJ 1999;319:19-23. Ref ID: 19268
180. Eaton T, Garrett JE, Young P, Fergusson W, Kolbe J, Rudkin S et al. Ambulatory oxygen improves quality of life of COPD patients: A randomised controlled study. European Respiratory Journal 2002;20:306-12. Ref ID: 19414
181. Crockett AJ, Cranston JM, Moss JR, Alpers JH. A review of long-term oxygen therapy for chronic obstructive pulmonary disease. Respir Med 2001;95:437-43. Ref ID: 1797
182. Andersson A, Strom K, Brodin H, Alton M, Boman G, Jakobsson P et al. Domiciliary liquid oxygen versus concentrator treatment in chronic hypoxaemia: a cost-utility analysis. Eur Respir J 1998;12:1284-9. Ref ID: 19269
183. Okubadejo AA, Paul EA, Wedzicha JA. Domiciliary oxygen cylinders: indications, prescription and usage. Respir Med 1994;88:777-85. Ref ID: 12336
184. Woodcock AA, Gross ER, Geddes DM. Oxygen relieves breathlessness in "pink puffers" Lancet 1981;1:907-9. Ref ID: 19270
185. Evans TW, Waterhouse JC, Carter A, Nicholl JF, Howard P. Short burst oxygen treatment for breathlessness in chronic obstructive airways disease. Thorax 1986;41:611-5. Ref ID: 4901
186. Swinburn CR, Mould H, Stone TN, Corris PA, Gibson GJ. Symptomatic benefit of supplemental oxygen in hypoxemic patients with chronic lung disease. Am Rev Respir Dis 1991;143:913-5. Ref ID: 16419
187. Ambrosino N, Montagna T, Nava S, Negri A, Brega S, Fracchia C et al. Short term effect of intermittent negative pressure ventilation in COPD patients with respiratory failure. Eur Respir J 1990;3:502-8. Ref ID: 498
188. Meecham Jones DJ, Paul EA, Jones PW, Wedzicha JA. Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. American Journal of Respiratory & Critical Care Medicine 1995;152:538-44. Ref ID: 1469
189. Plant PK, Elliott MW. Management of ventilatory failure in COPD. Thorax 2003;58:537-42. Ref ID: 19274
190. Wijkstra PJ, Lacasse Y, Guyatt GH, Goldstein RS. Nocturnal non-invasive positive pressure ventilation for stable chronic obstructive pulmonary disease. [Cochrane Review]. The Cochrane Library.Oxford:Update Software 2003;Issue 3. Ref ID: 1482
191. Clini E, Sturani C, Rossi A, Viaggi S, Corrado A, Donner CF et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal 2002;20:529-38. Ref ID: 1301
192. Behnke RH, Blount SG, Bristow JD, Carrieri V, Pierce JA, Sasahara A et al. Primary prevention of pulmonary heart disease. Circulation 1970;41:A17-A23. Ref ID: 19276
193. Chetty KG, Brown SE, Light RW. Identification of pulmonary hypertension in chronic obstructive pulmonary disease from routine chest radiographs. Am Rev Respir Dis 1982;126:338-41. Ref ID: 3056
194. Miller MR, Gorecka DM, Bishop JM. Radiological prediction of pulmonary hypertension in chronic obstructive pulmonary disease. Eur Heart J 1984;5:581-7. Ref ID: 11143
195. Oswald-Mammosser M, Oswald T, Nyankiye E, Dickele MC, Grange D, Weitzenblum E. Non-invasive diagnosis of pulmonary hypertension in chronic obstructive pulmonary disease. Comparison of ECG, radiological measurements, echocardiography and myocardial scintigraphy. Eur J Respir Dis 1987;71:419-29. Ref ID: 12469
196. MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One Am J Respir Crit Care Med 1994;150:833-52. Ref ID: 19279
197. Weitzenblum E, Zielinski J, Bishop JM. The diagnosis of "cor pulmonale" by non-invasive methods: a challenge for pulmonologists and cardiologists. Bull Eur Physiopathol. Respir 1983;19:423-6. Ref ID: 19280
198. Danchin N, Cornette A, Henriquez A, Godenir JP, Ethevenot G, Polu JM et al. Two-dimensional echocardiographic assessment of the right ventricle in patients with chronic obstructive lung disease. Chest 1987;92:229-33. Ref ID: 3814
199. Starling MR, Crawford MH, Sorensen SG, O'Rourke RA. A new two-dimensional echocardiographic technique for evaluating right ventricular size and performance in patients with obstructive lung disease. Circulation 1982;66:612-20. Ref ID: 15972
200. Turnbull LW, Ridgway JP, Biernacki W, McRitchie H, Muir AL, Best JJ et al. Assessment of the right ventricle by magnetic resonance imaging in chronic obstructive lung disease. Thorax 1990;45:597-601. Ref ID: 17150
201. Altschule MD. Limited usefulness of the so-called ejection fraction measurement in clinical practice. Chest 1986;90:134-5. Ref ID: 472
202. MacNee W, Morgan AD, Wathen CG, Muir AL, Flenley DC. Right ventricular performance during exercise in chronic obstructive pulmonary disease. The effects of oxygen. Respiration 1985;48:206-15. Ref ID: 10067
203. Zielinski J, Hawrylkiewicz I, Gorecka D, Gluskowski J, Koscinska M. Captopril effects on pulmonary and systemic hemodynamics in chronic cor pulmonale. Chest 1986;90:562-5. Ref ID: 19282
204. Kiely DG, Cargill RI, Wheeldon NM, Coutie WJ, Lipworth BJ. Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale. Cardiovasc Res 1997;33:201-8. Ref ID: 8568
205. Saadjian AY, Philip-Joet FF, Vestri R, Arnaud AG. Long-term treatment of chronic obstructive lung disease by Nifedipine: an 18-month haemodynamic study. Eur Respir J 1988;1:716-20. Ref ID: 14486
206. Johnson DC, Joshi RC, Mehta R, Cunnington AR. Acute and long term effect of nifedipine on pulmonary hypertension secondary to chronic obstructive airways disease. Eur J Respir Dis Suppl 1986;146:495-502. Ref ID: 7959
207. Gould L, Zahir M, DeMartino A, Gomprecht RF. Haemodynamic effects of phentolamine in chronic obstructive pulmonary disease. Br Heart J 1971;33:445-50. Ref ID: 6142
208. Van Mieghem W, De Backer G, De Wispelaere B, Billiet L, Cosemans J. Phentolamine infusion in cor pulmonale due to chronic obstructive pulmonary disease. Acta Cardiol 1978;33:253-62. Ref ID: 19283
209. Vik-Mo H, Walde N, Jentoft H, Halvorsen FJ. Improved haemodynamics but reduced arterial blood oxygenation, at rest and during exercise after long-term oral prazosin therapy in chronic cor pulmonale. Eur Heart J 1985;6:1047-53. Ref ID: 19284
210. Green LH, Smith TW. The use of digitalis in patients with pulmonary disease. Ann Intern Med 1977;87:459-65. Ref ID: 6210
211. Jezek V, Schrijen F. Haemodynamic effect of deslanoside at rest and during exercise in patients with chronic bronchitis. Br Heart J 1973;35:2-8. Ref ID: 7915
212. Brown SE, Pakron FJ, Milne N, Linden GS, Stansbury DW, Fischer CE et al. Effects of digoxin on exercise capacity and right ventricular function during exercise in chronic airflow obstruction. Chest 1984;85:187-91. Ref ID: 2209
213. British Thoracic Society Standards of Care Subcommittee on Pulmonary Rehabilitation. Pulmonary rehabilitation. Thorax 2001;56:827-34. Ref ID: 1223
214. Lacasse Y, Brosseau L, Milne S, Martin S, Wong E, Guyatt GH et al. Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease.(Cochrane Review). The Cochrane Library.Oxford:Update Software 2003;Issue 3. Ref ID: 1157
215. Ries AL, Carlin BW, Carrieri-Kohlman V, Casaburi R, Celli BR, Emery CF et al. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based guidelines. Chest 1997;112:1363-96. Ref ID: 63
216. Salman GF, Mosier MC, Beasley BW, Calkins DR. Rehabilitation for patients with chronic obstructive pulmonary disease: Meta-analysis of randomized controlled trials. Journal of General Internal Medicine 2003;18:213-21. Ref ID: 19351
217. Toshima MT, Blumberg E, Ries AL, Kaplan RM. Does rehabilitation reduce depression in patients with chronic obstructive pulmonary disease? Journal of Cardiopulmonary Rehabilitation 1992;12:261-9. Ref ID: 1024
218. Griffiths TLB. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial [published erratum appears in Lancet 2000 Apr 8;355(9211):1280]. Lancet 2000;355:362-8. Ref ID: 1041
219. Ries AL, Kaplan RM, Limberg TMK, Prewitt LM. Effects of pulmonary rehabilitation on physiological and psychosocial outcomes in patients with chronic obstructive pulmonary-disease. Annals of Internal Medicine 1995;122:823-32. Ref ID: 49
220. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Longitudinal trends in exercise capacity and health status after pulmonary rehabilitation in patients with COPD. Respiratory Medicine 2003;97:173-80. Ref ID: 19371
221. McBride A and Milne R. Hospital based pulmonary rehabilitation programmes for patients with severe chronic obstructive pulmonary disease. Southampton: Wessex Institute for Health Research and Development; 1999. Development and evaluation committee report number:94. Ref ID: 19346
222. Griffiths TL, Phillips CJ, Davies S, Burr ML, Campbell IA. Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation programme. Thorax 2001;56:779-84. Ref ID: 6262
223. Smith K, Cook D, Guyatt GH, Madhavan J, Oxman AD. Respiratory muscle training in chronic airflow limitation: a meta-analysis. American Review of Respiratory Disease 1992;145:533-9. Ref ID: 894
224. Lotters F, van Tol B, Kwakkel G, Gosselink R. Effects of controlled inspiratory muscle training in patients with COPD: a meta-analysis. European Respiratory Journal 2002;20:570-6. Ref ID: 1227
225. Ortega F, Toral J, Cejudo P, Villagomez R, Sanchez H, Castillo J et al. Comparison of effects of strength and endurance training in patients with chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine 2002;166:669-74. Ref ID: 19373
226. Puente-Maestu L, Sanz ML, Sanz P, Cubillo JM, Mayol J, Casaburi R. Comparison of effects of supervised versus self-monitored training programmes in patients with chronic obstructive pulmonary disease. European Respiratory Journal 2000;15:517-25. Ref ID: 1228
227. Berry MJ, Rejeski WJ, Adair NE, Ettinger Jr WH, Zaccaro DJ, Sevick MA. A randomized, controlled trial comparing long-term and short-term exercise in patients with chronic obstructive pulmonary disease. Journal of Cardiopulmonary Rehabilitation 2003;23:60-8. Ref ID: 19370
228. Young P, Dewse M, Fergusson W, Kolbe J. Respiratory rehabilitation in chronic obstructive pulmonary disease: Predictors of nonadherence. European Respiratory Journal 1999;13:855-9. Ref ID: 1040
229. Foglio K, Bianchi L, Ambrosino N. Is it really useful to repeat outpatient pulmonary rehabilitation programs in patients with chronic airway obstruction? A 2-year controlled study. Chest 2001;119:1696-704. Ref ID: 1045
230. National Institute for Clinical Excellence. Guidance on the use of zanamivir, amantadine and oseltamivir for the treatment of influenza. NICE technology appraisal guidance-No.58. 2003. London. National Institute for Clinical Excellence. Ref ID: 1789
231. Poole PJ, Chacko E, Wood-Baker RWB, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease.(Cochrane Review). The Cochrane Library.Oxford:Update Software 2003;Issue 3. Ref ID: 1523
232. Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med 1999;130:397-403. Ref ID: 1724
233. National Institute of Clinical Excellence. Guidance on the use of Zanamivir (Relenza) in the treatment of influenza. NICE technology appraisal guidance-No.15. 2000. London. National Institute of Clinical Excellence. Ref ID: 1715
234. Turner, D., Wailoo, A., Nicholson, K., Cooper, N., Sutton, A., Abrams, K., and NICE. Systematic Review and Economic Decision Modelling for the Prevention and Treatment of Influenza A and B. 28-4-2002. University of Leciester; ScHARR at University of Sheffield, NICE. Ref ID: 1786
235. Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Archives of Internal Medicine 1999;159:2437-42. Ref ID: 216
236. Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine 1999;17 Suppl 1:S91-S93. Ref ID: 1723
237. Leech JA, Gervais A, Ruben FL. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal 1987;136:361-5. Ref ID: 1620
238. Tandon MK, Gebski V. A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian & New Zealand Journal of Medicine 1991;21:427-32. Ref ID: 1618
239. Hak E, Van Essen GA, Buskens E, Stalman W, De Melker RA. Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, the Netherlands. Journal of Epidemiology and Community Health 1998;52:120-5. Ref ID: 108
240. Letter from the Chief Medical Officer, the Chief Nursing Officer and the Chief Pharmaceutical Officer. Update on Immunisation issues. PL/CMO/2003/4). 2003. Ref ID: 19492
241. The Department of Heath. Immunisation Against Infectious Disease ("The Green Book"). 1996. London. Department of Health. Ref ID: 19286
242. The Department of Heath. Pneumococcal (Draft Replacement Chapter). In: Immunisation Against Infectious Disease ("The Green Book"), London: Department of Health, 2003. Ref ID: 19493
243. Snider GL. Reduction pneumoplasty for giant bullous emphysema. Implications for surgical treatment of nonbullous emphysema. Chest 1996;109:540-8. Ref ID: 15767
244. Stirling GR, Babidge WJ, Peacock MJ, Smith JA, Matar KS, Snell GI et al. Lung volume reduction surgery in emphysema: a systematic review. Ann Thorac Surg 2001;72:641-8. Ref ID: 16105
245. Pompeo E, Marino M, Nofroni I, Matteucci G, Mineo TC. Reduction pneumoplasty versus respiratory rehabilitation in severe emphysema: a randomized study. Pulmonary Emphysema Research Group. Ann Thorac Surg 2000;70:948-53. Ref ID: 13344
246. National Emphysema Treatment Trial Research Group. A randomised trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. The New England Journal of Medicine 2003;348:2059-73. Ref ID: 1788
247. National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med 2001;345:1075-83. Ref ID: 19288
248. Zenati M, Keenan RJ, Courcoulas AP, Griffith BP. Lung volume reduction or lung transplantation for end-stage pulmonary emphysema? Eur J Cardiothorac. Surg 1998;14:27-31. Ref ID: 19289
249. Gaissert HA, Trulock EP, Cooper JD, Sundaresan RS, Patterson GA. Comparison of early functional results after volume reduction or lung transplantation for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg 1996;111:296-306. Ref ID: 5568
250. Keller CA, Naunheim KS, Osterloh J, Krucylak PE, Baudendistel L, McBride L et al. Hemodynamics and gas exchange after single lung transplantation and unilateral thoracoscopic lung reduction. J Heart Lung Transplant 1997;16:199-208. Ref ID: 8421
251. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: eighteenth Official Report-2001. J Heart Lung Transplant 2001;20:805-15. Ref ID: 7305
252. Cassivi SD, Meyers BF, Battafarano RJ, Guthrie TJ, Trulock EP, Lynch JP et al. Thirteen-year experience in lung transplantation for emphysema. Ann Thorac Surg 2002;74:1663-9. Ref ID: 2726
253. American Thoracic Society, Aris R, Barbers RG, Barst R, Baz MA, de Boer W et al. International guidelines for the selection of lung transplant candidates. Am J Respir Crit Care Med 1998;158:335-9. Ref ID: 513
254. Geddes D, Davies M, Koyama H, Hansell D, Pastorino U, Pepper J et al. Effect of lung-volume-reduction surgery in patients with severe emphysema. New England Journal of Medicine 2000;343:239-45. Ref ID: 227
255. Trulock EP, III. Lung Transplantation for COPD. Chest 1998;113(4):269S-276S. Ref ID: 17086
256. Eriksson S. A 30-year perspective on alpha(1)-antitrypsin deficiency. Chest 1996;110:S237-S242. Ref ID: 144
257. Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DCS, Ulrik CS et al. A randomized clinical trial of alpha1-antitrypsin augmentation therapy. American Journal of Respiratory & Critical Care Medicine 1999;160:1468-72. Ref ID: 1249
258. The Alpha 1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha 1-antitrypsin. American Journal of Respiratory & Critical Care Medicine 1998;158:49-59. Ref ID: 1336
259. Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A, Kok JA et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? European Respiratory Journal 1997;10:2260-3. Ref ID: 1258
260. Hay JW, Robin ED. Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease. American Journal of Public Health 1991;81:427-33. Ref ID: 1253
261. Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. (Cochrane Review). The Cochrine Library.Oxford:Update Software 2003;Issue 3. Ref ID: 100
262. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clinical Therapeutics 2000;22:209-21. Ref ID: 874
263. Stey C, Steurer J, Bachmann S, Medici TC, Tramer MR. The effect of oral N-acetylcysteine in chronic bronchitis: A quantitative systematic review. European Respiratory Journal 2000;16:253-62. Ref ID: 923
264. Cattaneo C. Neltenexine tablets in smoking and non-smoking patients with COPD. A double-blind, randomised, controlled study versus placebo. Minerva Medica. 2001;92:277-84. Ref ID: 1421
265. Gerrits CMJM, Herings RMC, Leufkens HGM, Lammers JWJ. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J 2003;21:795-8. Ref ID: 1794
266. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2001;322:1271-4. Ref ID: 863
267. Petty TL. The national mucolytic study. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest 1990;97:75-83. Ref ID: 1403
268. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Cost-effectiveness analysis of oral N-acetylcysteine as a preventive treatment in chronic bronchitis. Pharmacological Research 2000;42:39-50. Ref ID: 922
269. MacNee W. Oxidants/antioxidants and chronic obstructive pulmonary disease: pathogenesis to therapy. Novartis Found Symp 2001;234:169-85. Ref ID: 10055
270. Rahman I, MacNee W. Regulation of redox glutathione levels and gene transcription in lung inflammation: therapeutic approaches. Free Radic Biol Med 2000;28:1405-20. Ref ID: 13662
271. Rautalahti M, Virtamo J, Haukka J, Heinonen OP, Sundvall J, Albanes D et al. The effect of alpha-tocopherol and beta-carotene supplementation on COPD symptoms. American Journal of Respiratory & Critical Care Medicine 1997;156:1447-52. Ref ID: 1449
272. The ATBC Cancer Prevention Study Group. The alpha tocopherol, beta carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. Annals of Epidemiology 1994;4:1-10. Ref ID: 1530
273. Aversa C, Cazzola M, Clini V, Dal Negro R, Maiorano V, Tana F et al. Clinical trial of the efficacy and safety of moguisteine in patients with cough associated with chronic respiratory diseases. Drugs Under Experimental & Clinical Research 1993;19:273-9. Ref ID: 1231
274. Barnabe R, Berni F, Clini V, Pirrelli M, Pisani CA, Robusch M et al. The efficacy and safety of moguisteine in comparison with codeine phosphate in patients with chronic cough. Monaldi Archives for Chest Disease 1995;50:93-7. Ref ID: 1232
275. Del Donno M, Aversa C, Corsico R, Foresi A, Grassi V, Malerba M et al. Efficacy and safety of moguisteine in comparison with dextromethorphan in patients with persistent cough. Drug Investigation 1994;7:93-100. Ref ID: 1233
276. Sergysels R, Art G. A double-masked, placebo-controlled polysomnographic study of the antitussive effects of helicidine. Current Therapeutic Research, Clinical & Experimental 2001;62:35-47. Ref ID: 1238
277. Wojcicki J, Szwed G, Drozdowska KD. The antitussive and expectorant drug Duopect evaluated by the preferential test. Archivum Immunologiae et Therapiae Experimentalis 1976;24:549-52. Ref ID: 80
278. Staykova T, Black P, Chacko E, Ram FSF, Poole P. Prophyactic antibiotic therapy for chronic bronchitis. (Cochrane Review). The Cochrane Library.Oxford:Update Software 2003;Issue 3. Ref ID: 19362
279. Francis R. Chemotherapy in chronic bronchitis. Influence of daily penicillin and tetracycline on exacerbations and their cost. BMJ 1960. Ref ID: 1380
280. Gosling, W. R. O., Djajadinigrat, R. J., Bergstein, P. G. M., and Holle, P. Continuous suppressive antimicrobial treament in chronic infected bronchitis during the winter months. Diseases of the Chest (376), 380. 1967. Ref ID: 19452
281. Johnston, R. N., Lockhart, W., Smith, D. H., and Cadman, N. k. A trial of phenethicillin in chronic bronchitis. BMJ, 985-986. 1961. Ref ID: 19453
282. Johnston RN, McNeill RS, Smith DH, Dempster MB, Nairn JR, Purvis MS et al. Five-year winter chemoprophylaxis for chronic bronchitis. British Medical Journal 1969;4:265-9. Ref ID: 1274
283. Liippo, K., Pelliniemi, T. T., and Lehto, H. Trimethoprim prophylaxis of acute exacerbations in chronic obstructive pulmonary disease. Acta Medica Scandinavica , 455-459. 1987. Ref ID: 19454
284. Moyes, E. N. and Kershaw, R. A. Long-continued treatment with tetracycline and prednisolone in chronic bronchitis. Lancet , 1187-1191. 1957. Ref ID: 19455
285. Murdoch, J. McC., Leckie, W. J. H., Downie, J., Swain, R. H. A., and Gould, J. C. An evaluation of continuous antibiotic therapy in chronic bronchitis. BMJ , 1277-1285. 1959. Ref ID: 19456
286. Pridie R. A trial of continuous winter chemotherapy in chronic bronchitis. Lancet 1960. Ref ID: 1376
287. Working Party of the Medical Research Council. Value of chemoprophylaxis and chemotherapy in early chronic bronchitis. A report to the Medical Reserach Council by their Working Party on Trials of Chemotherapy in Early Chronic Bronchitis. BMJ , 1317-1322. 1966. Ref ID: 19451
288. Haas H, Morris JF, Samson S. Effect of oral penicillin on pneumococcal carriage in elderly men with chronic bronchitis. Clinical Therapeutics 1986;8:301-8. Ref ID: 154
289. Suzuki T, Yanai M, Yamaya M, Satoh NT, Sekizawa K, Ishida S et al. Erythromycin and common cold in COPD. Chest 2001;120:730-3. Ref ID: 1148
290. MRC,.Fletcher. Value of Chemoprophylaxis and chemotherapy in early chronic bronchitis. A report to the Medical Research Council by their working party on trials of chemotherapy in early chronic bronchitis. BMJ 1966;1:1317-22. Ref ID: 1317
291. Pines A. Controlled trials of a sulphonamide given weekly to prevent exacerbations of chronic bronchitis. BMJ 1967. Ref ID: 1377
292. Moher D, Schulz K, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;357:1191-4. Ref ID: 19292
293. Hahn HH, MacGregor RR, Avent CK, Counts GW, Smith HE, Beaty HN. Ampicillin and tetracycline in the treatment and prophylaxis of chronic bronchitis. Antimicrobial Agents & Chemotherapy 1972;2:45-8. Ref ID: 267
294. Grob PR, White E, Gargan R, Gibbs FJ. The use of erythromycin as prophylaxis in chronic bronchitis: a cohort study from general practice. Journal of International Medical Research 1980;8:Suppl 2:47-50. Ref ID: 1273
295. Pugh DL, Holland EE. Chemoprophylaxis in chronic bronchitis. Antiseptic 1974;71:261-7. Ref ID: 1278
296. McVay L. Antibiotic prophylaxis in chronic respiratory diseases. Arch Intern Med 1953;92:833-46. Ref ID: 1370
297. Buchanan J. Long-term prophylactic administration of tetracycline to chronic bronchitics. Lancet 1958. Ref ID: 1378
298. Cherniack N. Long-term treatment of bronchiectasis and chronic bronchitis. Archives of Internal Medicine 1959;103:345-53. Ref ID: 1379
299. Francis R. Chemotherapy of bronchitis. Influence of penicillin and tetracycline administered daily, or intermittently for exacerbations. BMJ 1961. Ref ID: 1381
300. Cooper J, Inman J, Currie W. Prophylactic treatment of chronic bronchitis comparing cotrimoxazole and amoxycillin. British Journal of Clinical Practice 1975;29:307-10. Ref ID: 1382
301. Specialist Nurse Innovations for COPD Review. Barts and The London. 2003. www.smd.gmul.ac.uk/gp/ copdreview/copdreview.html Ref ID: 19497
302. Smith B, Appleton S, Adams R, Southcott A, Ruffin R. Home care by outreach nursing for chronic obstructive pulmonary disease. (Cochrane Review). The Cochrane Library.Oxford:Update Software 2003;Issue 3. Ref ID: 1134
303. Thomas M, McKinley RK, Freeman E, Foy C, Prodger P, Price D. Breathing retraining for dysfunctional breathing in asthma: a randomised controlled trial. Thorax 2003;58:110-5. Ref ID: 19291
304. Rivington-Law BA, Epstein SW, Thompson GL, Corey PN. Effect of chest wall vibrations on pulmonary function in chronic bronchitis. Chest. 1984;85:378-81. Ref ID: 1353
305. Kurabayashi H, Machida I, Tamura K, Iwai F, Tamura J, Kubota K. Breathing out into water during subtotal immersion: A therapy for chronic pulmonary emphysema. American Journal of Physical Medicine & Rehabilitation 2000;79:150-3. Ref ID: 1654
306. Mohsenifar Z, Rosenberg N, Goldberg HS, Koerner SK. Mechanical vibration and conventional chest physiotherapy in outpatients with stable chronic obstructive lung disease. Chest 1985;87:483-5. Ref ID: 1655
307. Olseni L, Midgren B, Hornblad Y, Wollmer P. Chest physiotherapy in chronic obstructive pulmonary disease: Forced expiratory technique combined with either postural drainage or positive expiratory pressure breathing. Respiratory Medicine 1994;88:435-40. Ref ID: 1656
308. Savci S, Ince DI, Arikan H. A comparison of autogenic drainage and the active cycle of breathing techniques in patients with chronic obstructive pulmonary diseases. Journal of Cardiopulmonary Rehabilitation 2000;20:37-43. Ref ID: 1658
309. Van Hengstum M, Festen J, Beurskens C, Hankel M, Beekman F, Corstens F. Effect of positive expiratory pressure mask physiotherapy (PEP) versus forced expiration technique (FET/PD) on regional lung clearance in chronic bronchitis. European Respiratory Journal 1991;4:651-4. Ref ID: 1660
310. Kolaczkowski W, Taylor R, Hoffstein V. Improvement in oxygen saturation after chest physiotherapy in patients with emphysema. Physiotherapy Canada 1989;41:18-23. Ref ID: 1652
311. Christensen EF, Nedergaard T, Dahl R. Long-term treatment of chronic bronchitis with positive expiratory pressure mask and chest physiotherapy. Chest 1990;97:645-50. Ref ID: 1651
312. Casciari RJ, Fairshter RD, Harrison A. Effects of breathing retraining in patients with chronic obstructive pulmonary disease. Chest 1981;79:393-8. Ref ID: 1645
313. van Ede L, Yzermans CJ, Brouwer HJ. Prevalence of depression in patients with chronic obstructive pulmonary disease: a systematic review. Thorax 1999;54:688-92. Ref ID: 877
314. Rose C, Wallace L, Dickson R, Ayres J, Lehman R, Searle Y et al. The most effective psychologically-based treatments to reduce anxiety and panic in patients with chronic obstructive pulmonary disease (COPD): A systematic review. Patient Education & Counseling 2002;47:311-8. Ref ID: 1239
315. Borson S, McDonald GJ, Gayle T, Deffenbach MPHM, Lakshminarayan S, Vantuinen C. Improvement in mood, physical symptoms, and function with nortripryline for depression in patients with chronic obstructive pulmonary-disease. Psychosomatics 1992;33:190-201. Ref ID: 121
316. Kunik ME, Braun U, Stanley MA, Wristers K, Molinari V, Stoebner D et al. One session cognitive behavioural therapy for elderly patients with chronic obstructive pulmonary disease. Psychological Medicine 2001;31:717-23. Ref ID: 412
317. Man GC, Hsu K, Sproule BJ. Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest 1986;90:832-6. Ref ID: 1566
318. Kozora E, Vu TZ, Make B. Neurobehavioral improvement after brief rehabilitation in patients with chronic obstructive pulmonary disease. Journal of Cardiopulmonary Rehabilitation 2002;22:426-30. Ref ID: 1563
319. van Manen JG, Bindels PJ, Dekker FW, IJzermans CJ, van der Zee JS, Schade E. Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax. 2002;57:412-6. Ref ID: 1576
320. Yohannes AM, Roomi J, Baldwin RC, Connolly MJ. Depression in elderly outpatients with disabling chronic obstructive pulmonary disease. Age & Ageing 1998;27:155-60. Ref ID: 1581
321. Yohannes AM, Baldwin RC, Connolly MJ. Depression and anxiety in elderly outpatients with chronic obstructive pulmonary disease: Prevalence, and validation of the BASDEC screening questionnaire. International Journal of Geriatric Psychiatry 2000;15:1090-6. Ref ID: 1358
322. Lacasse Y, Rousseau L, Maltais F. Prevalence of depressive symptoms and depression in patients with severe oxygen-dependent chronic obstructive pulmonary disease. Journal of Cardiopulmonary Rehabilitation 2001;21:80-6. Ref ID: 1564
323. Crockett AJ, Cranston JM, Moss JR, Alpers JH. The impact of anxiety, depression and living alone in chronic obstructive pulmonary disease. Quality of Life Research. 2002;11:309-16. Ref ID: 1553
324. Dowson C, Laing R, Barraclough R, Town I, Mulder R, Norris K et al. The use of the Hospital Anxiety and Depression Scale (HADS) in patients with chronic obstructive pulmonary disease: a pilot study. New Zealand Medical Journal. 2001;114:447-9. Ref ID: 1555
325. Withers NJ, Rudkin ST, White RJ. Anxiety and depression in severe chronic obstructive pulmonary disease: The effects of pulmonary rehabilitation. Journal of Cardiopulmonary Rehabilitation 1999;19:362-5. Ref ID: 1577
326. Yohannes AM, Baldwin RC, Connolly M. Mortality predictors in disabling chronic obstructive pulmonary disease in old age. Age & Ageing. 2002;31:137-40. Ref ID: 1579
327. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr. Scand 1983;67:361-70. Ref ID: 19293
328. Okubadejo AA, Paul EA, Jones PW, Wedzicha JA. Does long-term oxygen therapy affect quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia? European Respiratory Journal 1996;9:2335-9. Ref ID: 1761
329. Yohannes AM, Connolly MJ, Baldwin RC. A feasibility study of antidepressant drug therapy in depressed elderly patients with chronic obstructive pulmonary disease. International Journal of Geriatric Psychiatry 2001;16:451-4. Ref ID: 1102
330. Schols AM, Wouters EF. Nutritional abnormalities and supplementation in chronic obstructive pulmonary disease. Clin Chest Med 2000;21:753-62. Ref ID: 850
331. Agusti AG. Systemic effects of chronic obstructive pulmonary disease. Novartis Found Symp 2001;234:242-9. Ref ID: 341
332. Ferreira IM, Brooks D, Lacasse Y, Goldstein RS, White J. Nutritional supplementation for stable chronic obstructive pulmonary disease.(Cochrane Review). The Cochrane Library.Oxford:Update Software 2003;Issue 3. Ref ID: 1503
333. Otte KE, Ahlburg P, D'Amore F, Stellfeld M. Nutritional repletion in malnourished patients with emphysema. Journal of Parenteral & Enteral Nutrition 1989;13:152-6. Ref ID: 289
334. Slinde F, Gronberg AM, Engstrom CR, Rossander-Hulthen L, Larsson S. Individual dietary intervention in patients with COPD during multidisciplinary rehabilitation. Respiratory Medicine. 2002;96:330-6. Ref ID: 1514
335. Schols AMWJ, Mostert R, Soeters PB, Greve LH, Wouters EFM. Nutritional state and exercise performance in patients with chronic obstructive lung disease. Thorax 1989;44:937-41. Ref ID: 281
336. Baarends EM, Schols AM, Mostert R, Wouters EF. Peak exercise response in relation to tissue depletion in patients with chronic obstructive pulmonary disease. European Respiratory Journal. 1997;10:2807-13. Ref ID: 1587
337. Engelen MP, Schols AM, Baken WC, Wesseling GJ, Wouters EF. Nutritional depletion in relation to respiratory and peripheral skeletal muscle function in out-patients with COPD. European Respiratory Journal. 1994;7:1793-7. Ref ID: 1591
338. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine. 1999;160:1856-61. Ref ID: 1596
339. Marquis K, Debigare R, Lacasse Y, LeBlanc P, Jobin J, Carrier G et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine. 2002;166:809-13. Ref ID: 1598
340. Prescott E, Almdal T, Mikkelsen KL, Tofteng CL, Vestbo J, Lange P. Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. European Respiratory Journal. 2002;20:539-44. Ref ID: 1603
341. Sahebjami H, Doers JT, Render ML, Bond TL. Anthropometric and pulmonary function test profiles of outpatients with stable chronic obstructive pulmonary disease. American Journal of Medicine 1993;94:469-74. Ref ID: 1605
342. Wilson DO, Rogers RM, Wright EC, Anthonisen NR. Body weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. American Review of Respiratory Disease. 1989;139:1435-8. Ref ID: 1610
343. Gray-Donald K, Gibbons L, Shapiro SH, Martin JG. Effect of nutritional status on exercise performance in patients with chronic obstructive pulmonary disease. American Review of Respiratory Disease. 1989;140:1544-8. Ref ID: 1613
344. Schols AMWJ, Soeters PB, Dingemans AMC, Mostert R, Frantzen PJ, Wouters EFM. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. American Review of Respiratory Disease 1993;147:1151-6. Ref ID: 1614
345. Sahebjami H, Sathianpitayakul E. Influence of body weight on the severity of dyspnea in chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine 2000;161:886-90. Ref ID: 1616
346. Schols AMWJ, Slangen J, Volovics L, Wouters EFM. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 1998;157:1791-7. Ref ID: 8
347. Palange P, Forte S, Felli A, Galassetti P, Serra P, Carlone S. Nutritional state and exercise tolerance in patients with COPD. Chest 1995;107:1206-12. Ref ID: 1601
348. Rogers RM, Donahoe M, Costantino J. Physiologic effects of oral supplemental feeding in malnourished patients with chronic obstructive pulmonary disease. A randomized control study. American Review of Respiratory Disease. 1992;146:1511-7. Ref ID: 1612
349. Koplemann, P. G. and The members of the working party. Nutrition and patients a doctors responsibility. RCP London. 1-97. 2002. London, RCP. Ref ID: 19472
350. Roberts CM, Lowe D, Bucknall CE, Ryland I, Kelly Y, Pearson MG. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax 2002;57:137-41. Ref ID: 19252
351. Jennings AL, Davies AN, Higgins JPT, Broadley K. Opioids for the palliation of breathlessness in terminal illness. (Cochrane Review). The Cochrane Library.Oxford:Update Software 2003;Issue 3. Ref ID: 1716
352. Elkington H, White P, Higgs R, Pettinari CJ. GPs' views of discussions of prognosis in severe COPD. Family Practice 2001;18:440-4. Ref ID: 117
353. Sullivan KE, Hebert PC, Logan J, O'Connor AM, McNeely PD. What do physicians tell patients with end-stage COPD about intubation and mechanical ventilation? Chest. 1996;109:258-64. Ref ID: 1528
354. Rhodes P. Focus on palliative care. Palliative care: the situation of people with chronic respiratory disease. British Journal of Community Nursing 1999;4:131-6. Ref ID: 1545
355. Heffner JE, Fahy B, Hilling L, Barbieri C. Attitudes regarding advance directives among patients in pulmonary rehabilitation. Am J Respir Crit Care Med 1996;154:1735-40. Ref ID: 1717
356. Ramsdell JW, Henderson S, Renvall MJ, Salmon DP, Ferguson P. Effects of theophylline and ipratropium on cognition in elderly patients with chronic obstructive pulmonary disease. Annals of Allergy Asthma & Immunology 1996;76:335-40. Ref ID: 145
357. Hunt A. The elderly at home. A study of elderly people living in the community in England in 1976. London: OPCS, 1976. Ref ID: 19294
358. Yohannes AM, Roomi J, Connolly MJ. Elderly people at home disabled by chronic obstructive pulmonary disease. Age Ageing 1998;27:523-5. Ref ID: 19295
359. Yohannes AM, Greenwood YA, Connolly MJ. Reliability of the Manchester respiratory activities of daily living questionnaire as a postal questionnaire. Age Ageing 2002;31:355-8. Ref ID: 19296
360. Yohannes AM, Roomi J, Winn S, Connolly MJ. The Manchester Respiratory Activities of Daily Living questionnaire: development, reliability, validity, and responsiveness to pulmonary rehabilitation J Am Geriatr Soc 2000;48:1496-500. Ref ID: 19297
361. Garrod R, Bestall JC, Paul EA, Wedzicha JA, Jones PW. Development and validation of a standardized measure of activity of daily living in patients with severe COPD: the London Chest Activity of Daily Living scale (LCADL). Respir Med 2000;94:589-96. Ref ID: 5650
362. Garrod R, Paul EA, Wedzicha JA. An evaluation of the reliability and sensitivity of the London Chest Activity of Daily Living Scale (LCADL). Respir Med 2002;96:725-30. Ref ID: 5654
363. Law M, Polatajko H, Pollock N, McColl MA, Carswell A, Baptiste S. Pilot testing of the Canadian Occupational Performance Measure: clinical and measurement issues. Can J Occup Ther 1994;61:191-7. Ref ID: 9372
364. Sewell L, Singh SJ. The Canadian Occupational Performance Measure: Is it a reliable measure in clients with chronic obstructive pulmonary disease? British Journal of Occupational Therapy. 2001;64:305-10. Ref ID: 19495
365. Managing passengers with respiratory disease planning air travel: British Thoracic Society recommendations. Thorax 2002;57:289-304. Ref ID: 19298
366. Zaugg M, Kaplan V, Widmer U, Baumann PC, Russi EW. Fatal air embolism in an airplane passenger with a giant intrapulmonary bronchogenic cyst. Am J Respir Crit Care Med 1998;157:1686-9. Ref ID: 19299
367. Sassi-Dambron DE, Eakin EG, Ries AL, Kaplan RM. Treatment of dyspnea in COPD. A controlled clinical trial of dyspnea management strategies. Chest 1995;107:724-9. Ref ID: 62
368. Rowland J, Nelson EC, Barlow PB, McHugo G, Meier FA, Brent P et al. Chronic obstructive airway disease. Impact of health education. Chest 1986;90:233-8. Ref ID: 103
369. Gallefoss F, Bakke PS, Rsgaard PK. Quality of life assessment after patient education in a randomized controlled study on asthma and chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine 1999;159:812-7. Ref ID: 113
370. Gallefoss F, Bakke PS. How does patient education and self-management among asthmatics and patients with chronic obstructive pulmonary disease affect medication? American Journal of Respiratory & Critical Care Medicine 1999;160:2000-5. Ref ID: 114
371. Devine EC, Pearcy J. Meta-analysis of the effects of psychoeducational care in adults with chronic obstructive pulmonary disease. Patient Education & Counseling 1996;29:167-78. Ref ID: 78
372. Monninkhof EM, van der Valk PDLPM, van der Palen J, Van Herwaarden CLA, Partidge MR, Zielhuis GA. Self-management education for patients with chronic obstructive pulmonary disease (Cochrane review). The Cochrane Library.Oxford:Update Software 2003;Issue 3. Ref ID: 436
373. Bourbeau J, Julien M, Maltais F, Rouleau M, Beaupre A, Begin R et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease - A disease-specific self-management intervention. Archives of Internal Medicine 2003;163:585-91. Ref ID: 1712
374. Emery CF, Schein RL, Hauck ER, Maclntyre NR. Psychological and cognitive outcomes of a randomized trial of exercise among patients with chronic obstructive pulmonary disease. Health Psychology 1998;17:232-40. Ref ID: 1076
375. Blake RL, Jr., Vandiver TA, Braun S, Bertuso DD, Straub V. A randomized controlled evaluation of a psychosocial intervention in adults with chronic lung disease. Fam.Med 1990;22:365-70. Ref ID: 1800
376. Littlejohns P, Baveystock CM, Parnell H, Jones PW. Randomised controlled trial of the effectiveness of a respiratory health worker in reducing impairment, disability, and handicap due to chronic airflow limitation. Thorax 1991;46:559-64. Ref ID: 1801
377. Cockcroft A, Bagnall P, Heslop A, Andersson N, Heaton R, Batstone J et al. Controlled trial of respiratory health worker visiting patients with chronic respiratory disability. Br Med J (Clin Res Ed) 1987;294:225-8. Ref ID: 1803
378. Solomon DK, Portner TS, Bass GE, Gourley DR, Gourley GA, Holt JM et al. Clinical and economic outcomes in the hypertension and COPD arms of a multicenter outcomes study. J Am Pharm Assoc (Wash.) 1998;38:574-85. Ref ID: 1804
379. Gourley GA, Portner TS, Gourley DR, Rigolosi EL, Holt JM, Solomon DK et al. Humanistic outcomes in the hypertension and COPD arms of a multicenter outcomes study. J Am Pharm Assoc (Wash.) 1998;38:586-97. Ref ID: 1805
380. Watson PB, Town GI, Holbrook N, Dwan C, Toop LJ, Drennan CJ. Evaluation of a self-management plan for chronic obstructive pulmonary disease. European Respiratory Journal 1997;10:1267-71. Ref ID: 1096
381. Gallefoss F, Bakke PS. Impact of patient education and self-management on morbidity in asthmatics and patients with chronic obstructive pulmonary disease. Respir Med 2000;94:279-87. Ref ID: 1802
382. The Australian Lung Foundation. Chronic Obstructive Pulmonary Disease (COPD). Australian and New Zealand Management Guidelines. 2002. Lutwyche. Ref ID: 19438
383. NCEPOD. Extremes of age. The 1999 report of the national confidential enquiry into perioperative deaths. 1999. London. NCEPOD. Ref ID: 19304
384. Appleberg M, Gordon L, Fatti LP. Preoperative pulmonary evaluation of surgical patients using the vitalograph. Br J Surg 1974;61:57-9. Ref ID: 665
385. Kocabas A, Kara K, Ozgur G, Sonmez H, Burgut R. Value of preoperative spirometry to predict postoperative pulmonary complications. Respir Med 1996;90:25-33. Ref ID: 1807
386. Celli BR, Rodriguez KS, Snider GL. A controlled trial of intermittent positive pressure breathing, incentive spirometry, and deep breathing exercises in preventing pulmonary complications after abdominal surgery. Am Rev Respir Dis 1984;130:12-5. Ref ID: 2844
387. Saklad M. Grading of patients for surgical procedures. Anaesthesiology 1941;2:281-4. Ref ID: 14590
388. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117:3985-401S. Ref ID: 30
389. Garcia-Aymerich J, Monso E, Marrades RM, Escarrabill J, Felez MA, Sunyer J et al. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation - EFRAM Study. American Journal of Respiratory and Critical Care Medicine 2001;164:1002-7. Ref ID: 28
390. Connors AF, Dawson NV, Thomas C, Harrell FE, Desbiens N, Fulkerson WJ et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. American Journal of Respiratory and Critical Care Medicine 1996;154:959-67. Ref ID: 21
391. Seemungal TAR, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2000;161:1608-13. Ref ID: 6
392. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52. Ref ID: 19253
393. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 1998;157:1418-22. Ref ID: 20
394. Andersson F, Borg S, Jansson S-A, Jonsson A-C, Ericsson A, Prutz C et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respiratory Medicine 2002;96:700-8. Ref ID: 1365
395. Price MJ, Hurrell C. Health care costs of treating exacerbations of COPD. European Respiratory Journal 1999;14. Ref ID: 19322
396. Wedzicha JA. Exacerbations: etiology and pathophysiologic mechanisms. Chest 2002;121(5):136S-141S. Ref ID: 19254
397. Gravil JH, Al Rawas OA, Cotton MM, Flanigan U, Irwin A, Stevenson RD. Home treatment of exacerbations of chronic obstructive pulmonary disease by an acute respiratory assessment service. Lancet 1998;351:1853-5. Ref ID: 19
398. Killen J, Ellis H. Assisted discharge for patients with exacerbations of chronic obstructive pulmonary disease: safe and effective. Thorax 2000;55:885. Ref ID: 19439
399. Skwarska E, Cohen G, Skwarski KM, Lamb C, Bushell D, Parker S et al. Randomised controlled trial of supported discharge in patients with exacerbations of chronic obstructive pulmonary disease. Thorax 2000;55:907-12. Ref ID: 221
400. Davies L, Wilkinson M, Bonner S, Calverley PM, Angus RM. "Hospital at home" versus hospital care in patients with exacerbations of chronic obstructive pulmonary disease: prospective randomised controlled trial. BMJ 2000;321:1265-8. Ref ID: 1059
401. Ojoo JC, Moon T, McGlone S, Martin K, Gardiner ED, Greenstone MA et al. Patients' and carers' preferences in two models of care for acute exacerbations of COPD: results of a randomised controlled trial. Thorax 2002;57:167-9. Ref ID: 1130
402. Hernandez C, Casas A, Escarrabill J, Alonso J, Puig-Junoy J, Farrero E et al. Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients. European Respiratory Journal. 2003;21:58-67. Ref ID: 19473
403. Fried TR, Van Doom C, Tinetti ME, Drickamer MA. Older persons' preferences for site of treatment in acute illness. Journal of General Internal Medicine 1998;13:522-7. Ref ID: 1126
404. Fried TR, Van Doom C, O'Leary JR, Tinetti ME, Drickamer MA. Older persons' preferences for home vs hospital care in the treatment of acute illness. Archives of Internal Medicine 2000;160:1501-6. Ref ID: 1127
405. Cotton MM, Bucknall CE, Dagg KD, Johnson MK, MacGregor G, Stewart C et al. Early discharge for patients with exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial. Thorax. 2000;55:902-6. Ref ID: 220
406. Shepperd S, Harwood D, Jenkinson C, Gray A, Vessey M, Morgan P. Randomised controlled trial comparing hospital at home care with inpatient hospital care. I: three month follow up of health outcomes. British Medical Journal 1998;316:1786-91. Ref ID: 838
407. Turner MO, Patel A, Ginsburg S, FitzGerald JM. Bronchodilator delivery in acute airflow obstruction: A meta-analysis. Archives of Internal Medicine 1997;157:1736-44. Ref ID: 945
408. McCrory, D. C., Brown, C., Gray, R. N., Goslin, R. E., MacIntyre, N. R., Kolimaga, J. T., Oddone, E. Z., and Matchar, D. Management of acute exacerbations of chronic obstructive pulmonary disease. 256. 2001. Rockville, MD, USA, Agency for Healthcare Research and Quality. Ref ID: 1145
409. Wood-Baker R, Walters EH, Gibson P. Oral corticosteroids for acute exacerbations of chronic obstructive pulmonary disease (Cochrane Review). The Cochrane Library.Oxford:Update Software 2003;Issue 3. Ref ID: 1364
410. Singh JM, Palda VA, Stanbrook MB, Chapman KR. Corticosteroid therapy for pts with acute exacerbations of COPD: a systematic review. Archives of Internal Medicine 2002;162:2527-36. Ref ID: 1484
411. Bullard MJ, Liaw SJ, Tsai YH, Min HP. Early corticosteroid use in acute exacerbations of chronic airflow obstruction. American Journal of Emergency Medicine. 1996;14:139-43. Ref ID: 1360
412. Maltais F, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet N, Haddon J et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A randomized controlled trial. American Journal of Respiratory & Critical Care Medicine 2002;165:698-703. Ref ID: 1362
413. Davies L, Angus RM, Calverley PMA. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999;354:456-60. Ref ID: 217
414. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. New England Journal of Medicine 1999;340:1941-7. Ref ID: 36
415. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. American Journal of Respiratory and Critical Care Medicine 1996;154:407-12. Ref ID: 38
416. Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Annals of Internal Medicine. 1980;92:753-8. Ref ID: 1359
417. Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000;117:1638-45. Ref ID: 17
418. SIGN. Community Management of Lower Respiratory Tract Infection in Adults. SIGN publication No 59. 2002. SIGN. Ref ID: 1316
419. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary-disease exacerbations - a metaanalysis. Journal of the American Medical Association 1995;273:957-60. Ref ID: 44
420. Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: A randomised placebo-controlled trial. Lancet 2001;358(9298):2020-2025. Ref ID: 349
421. Sin DD, Tu JV. Outpatient antibiotic therapy and short term mortality in elderly patients with chronic obstructive pulmonary disease. Canadian Respiratory Journal 2000;7:466-71. Ref ID: 416
422. Allegra L, Blasi F, de Bernardi B, Cosentini R, Tarsia P. Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a re-evaluation of previously published data of a placebo-controlled randomized study. Pulmonary Pharmacology & Therapeutics 2001;14:149-55. Ref ID: 1151
423. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic-therapy in exacerbations of chronic obstructive pulmonary-disease. Annals of Internal Medicine 1987;106:196-204. Ref ID: 25
424. Elmes PC, King TK, Langlands JH, Mackay JA, Wallace WF, Wade OL et al. Value of ampicillin in the hospital treatment of exacerbations of chronic bronchitis. British Medical Journal 1965;5467:904-8. Ref ID: 1153
425. Berry DG, Fry J, Hindley CP. Exacerbations of chronic bronchitis: treatment with oxytetracycline. Lancet 1960;1:137-9. Ref ID: 19275
426. Davies BI, Maesen FP. Quinolones in chest infections. J Antimicrob.Chemother. 1986;18:296-9. Ref ID: 19277
427. Morris S, Anderson P, Irwin DE. Acute exacerbations of chronic bronchitis: a pharmacoeconomic review of antibacterial use. Pharmacoeconomics 2002;20:153-68. Ref ID: 19271
428. Backhouse R, Shakespeare A, Hutton J. Economic evaluation of alternative antibiotic regimens in the management of acute exacerbations of chronic bronchitis. British Journal of Medical Economics 1995;8:1-25. Ref ID: 19272
429. Torrance G, Walker V, Grossman R, Mukherjee J, Vaughan D, La Forge J et al. Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. Pharmacoeconomics 1999;16:499-520. Ref ID: 19273
430. Lakshminarayan S, Sahn SA, Weil JV. Effect of aminophylline on ventilatory responses in normal man. Am Rev Respir Dis 1978;117:33-8. Ref ID: 19440
431. Sanders JS, Berman TM, Bartlett MM, Kronenberg RS. Increased hypoxic ventilatory drive due to administration of aminophylline in normal men. Chest 1980;78:279-82. Ref ID: 19441
432. Sharp JT. Theophylline in chronic obstructive pulmonary disease. Journal Allergy Clin Immunol 1986;78:800-5. Ref ID: 19442
433. Barr RG, Rowe BH, Camargo CA, Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease. (Cochrane Review). The Cochrane Library.Oxford:Update Software 2003;Issue 3. Ref ID: 859
434. Murata GH, Gorby MS, Chick TW, Halperin AK. Aminophylline in the outpatient management of decompensated chronic obstructive pulmonary disease. Chest 1990;98:1346-50. Ref ID: 93
435. Murciano D, Auclair MH, Pariente R, Aubier M. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary-disease. New England Journal of Medicine 1989;320:1521-5. Ref ID: 201
436. Barbera JA, Reyes A, Roca J, Montserrat JM, Wagner PD, Rodriguez RR. Effect of intravenously administered aminophylline on ventilation/perfusion inequality during recovery from exacerbations of chronic obstructive pulmonary disease. American Review of Respiratory Disease 1992;145:1328-33. Ref ID: 1106
437. Rice KL, Leatherman JW, Duane PG, Snyder LS, Harmon KR, Abel J et al. Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. A controlled trial. Annals of Internal Medicine 1987;107:305-9. Ref ID: 1110
438. Seidenfeld JJ, Jones WN, Moss RE, Tremper J. Intravenous aminophylline in the treatment of acute bronchospastic exacerbations of chronic obstructive pulmonary disease. Ann Emerg Med 1984;13:248-52. Ref ID: 1111
439. Wrenn K, Slovis CM, Murphey F, Greenburg RS. Aminophylline therapy for acute bronchospastic disease in the emergency room. Annals of Internal Medicine 1991;115:241-7. Ref ID: 1289
440. Ram, F. S. F., Poole, P. J., Bagg, W., Stewart, J., and Black, P. N. Randomised, controlled trial of theophylline for the treatment of exacerbations of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 161 Suppl, A489. 2000. Ref ID: 19447
441. Greenstone M, Lasserson T. Doxapram for ventilatory failure due to exacerbations of chronic obstructive pulmonary disease. (Cochrane Review). The Cochrane Library.Chichester, UK: John Wiley & Sons, Ltd 2003;(4). Ref ID: 1290
442. Bardsley PA, Tweney J, Morgan N, Howard P. Oral almitrine in treatment of acute respiratory failure and cor pulmonale in patients with an exacerbation of chronic obstructive airways disease. Thorax 1991;46:493-8. Ref ID: 1334
443. Moser K. Respiratory stimulation with intravenous doxapram in respiratory failure. A double blind co-operative study. New England Journal of Medicine 1973;288:427-31. Ref ID: 1320
444. Angus RM, Ahmed AA, Fenwick LJ, Peacock AJ. Comparison of the acute effects on gas exchange of nasal ventilation and doxapram in exacerbations of chronic obstructive pulmonary disease. Thorax 1996;51:1048-50. Ref ID: 1293
445. Edwards. A double blind trial of five respiratory stimulants in patients with acute ventilation failure. Lancet 1967;2:226-9. Ref ID: 1319
446. Newman, W. J, Banham, S. J, Barr, J., Bell, D., Douglas, N. J., and Innes, A. J. A randomised trial comparing non-invasive ventilation with the respiratory stimulant, doxapram, in the treament of acute hypercapnic respiratory failure complicating exacerbations of chronic obstructive pulmonary disease. 2001. (Unpublished data). Ref ID: 19477
447. Murphy R, Driscoll P, O'Driscoll R. Emergency oxygen therapy for the COPD patient. Emergency Medicine Journal 2001;18:333-9. Ref ID: 1162
448. Murphy R, Mackway-Jones K, Sammy I, Driscoll P, Gray A, O'Driscoll R. Emergency oxygen therapy for the breathless patient. Guidelines prepared by the North West Oxygen Group. Emergency Medicine Journal 2001;18:421-3. Ref ID: 19443
449. Hutchison DCS, Flenley DC, Donald KW. Controlled oxygen therapy in respiratory failure. BMJ 1964;2:1159-66. Ref ID: 19307
450. Bone RC, Pierce AK, Johnson RL, Jr. Controlled oxygen administration in acute respiratory failure in chronic obstructive pulmonary disease: a reappraisal. Am J Med 1978;65:896-902. Ref ID: 19309
451. Agusti AG, Carrera M, Barbe F, Munoz A, Togores B. Oxygen therapy during exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1999;14:934-9. Ref ID: 19310
452. King TK, Ali N, Briscoe WA. Treatment of hypoxia with 24 percent oxygen. A new approach to the interpretation of data collected in a pulmonary intensive care unit. Am Rev Respir Dis 1973;108:19-29. Ref ID: 19312
453. Plant PK, Owen JL, Elliott MW. One year period prevalence study of respiratory acidosis in acute exacerbations of COPD: implications for the provision of non-invasive ventilation and oxygen administration. Thorax 2000;55:550-4. Ref ID: 13275
454. DeGaute JP, Domenighetti G, Naeije R, Vincent JL, Treyvaud D, Perret C. Oxygen delivery in acute exacerbation of chronic obstructive pulmonary disease. Effects of controlled oxygen therapy. Am Rev Respir Dis 1981;124:26-30. Ref ID: 4042
455. Smith JP, Stone RW, Muschenheim C. Acute respiratory failure in chronic lung disease. American Review of Respiratory Disease. 1968;97:791-803. Ref ID: 19315
456. Eldridge F, Gherman C. Studies of oxygen administration in respiratory failure. Ann Intern Med 1968;68:569-78. Ref ID: 4657
457. Prime FJ, Westlake EK. The respiratory response to CO2 in emphysema. Clin Sci 1954;13:321-32. Ref ID: 17344
458. Aubier M, Murciano D, Milic-Emili J, Touaty E, Daghfous J, Pariente R et al. Effects of the administration of O2 on ventilation and blood gases in patients with chronic obstructive pulmonary disease during acute respiratory failure. Am Rev Respir Dis 1980;122:747-54. Ref ID: 781
459. Fajac I, Texereau J, Rivoal V, Dessanges JF, Dinh-Xuan AT, Dall'Ava-Santucci J. Blood gas measurement during exercise: a comparative study between arterialized earlobe sampling and direct arterial puncture in adults. Eur Respir J 1998;11:712-5. Ref ID: 4961
460. Dall'Ava-Santucci J, Dessanges JF, Dinh Xuan AT, Lockhart A. Is arterialized earlobe blood PO2 an acceptable substitute for arterial blood PO2? Eur Respir J 1996;9:1329-30. Ref ID: 3791
461. Pitkin AD, Roberts CM, Wedzicha JA. Arterialised earlobe blood gas analysis: an underused technique. Thorax 1994;49:364-6. Ref ID: 13267
462. Sauty A, Uldry C, Debetaz LF, Leuenberger P, Fitting JW. Differences in PO2 and PCO2 between arterial and arterialized earlobe samples. Eur Respir J 1996;9:186-9. Ref ID: 19320
463. Peter JV, Moran JL, Phillips-Hughes J, Warn D. Noninvasive ventilation in acute respiratory failure - a meta-analysis update. Critical Care Medicine. 2002;30:555-62. Ref ID: 854
464. Keenan SP, Kernerman PD, Cook DJ, Martin CM, McCormack D, Sibbald WJ. Effect of noninvasive positive pressure ventilation on mortality in patients admitted with acute respiratory failure: a meta-analysis. Critical Care Medicine 1997;25:1685-92. Ref ID: 887
465. Ram FSF, Lightowler JVJ, Wedzicha JA. Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. (Cochrane Review). The Cochrane Library.Oxford:Update Software 2003;Issue 3. Ref ID: 1485
466. Thys F, Roeseler J, Reynaert M, Liistro G, Rodenstein DO. Noninvasive ventilation for acute respiratory failure: A prospective randomised placebo-controlled trial. European Respiratory Journal 2002;20:545-55. Ref ID: 1314
467. Conti G, Antonelli M, Navalesi P. Noninvasive vs conventional mechanical ventilation in pts with COPD after failure of medical treatment in the ward; a randomised trial. Intensive Care Medicine 2002;28:1701-7. Ref ID: 1486
468. Keenan SP, Gregor J, Sibbald WJ, Cook D, Gafni A. Noninvasive positive pressure ventilation in the setting of severe, acute exacerbations of chronic obstructive pulmonary disease: more effective and less expensive. Critical Care Medicine 2000;28:2094-102. Ref ID: 871
469. Plant PK, Owen JL, Parrott S, Elliott MW. Cost effectiveness of ward based non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease: economic analysis of randomised controlled trial. BMJ 2003;326:956. Ref ID: 19323
470. Seneff MG, Wagner DP, Wagner RP, Zimmerman JE, Knaus WA. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995;274:1852-7. Ref ID: 115
471. Esteban A, Anzueto A, Frutos F, Alia I, Brochard L, Stewart TE et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA 2002;287:345-55. Ref ID: 1307
472. Rieves RD, Bass D, Carter RR, Griffith JE, Norman JR. Severe COPD and acute respiratory failure. Correlates for survival at the time of tracheal intubation. Chest 1993;104:854-60. Ref ID: 1487
473. Nevins ML, Epstein SK. Predictors of outcome for patients with COPD requiring invasive mechanical ventilation. Chest 2001;119:1840-9. Ref ID: 1488
474. Nava S, Ambrosino N, Clini E, Prato M, Orlando G, Vitacca M et al. Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease. A randomized, controlled trial. Annals of Internal Medicine 1998;128:721-8. Ref ID: 1311
475. Jones AP, Rowe BH. Bronchopulmonary hygiene physical therapy for chronic obstructive pulmonary disease and bronchiectasis (Cochrane Review). The Cochrane Library.Oxford:Update Software 2003;Issue 3. Ref ID: 1345
476. Bellone A, Lascioli R, Raschi S, Guzzi L, Adone R. Chest physical therapy in patients with acute exacerbation of chronic bronchitis: Effectiveness of three methods. Archives of Physical Medicine & Rehabilitation 2000:81:558-60. Ref ID: 1338
477. Newton DA, Bevans HG. Physiotherapy and intermittent positive-pressure ventilation of chronic bronchitis. British Medical Journal. 1978;2:1525-8. Ref ID: 1341
478. Bellone A, Spagnolatti L, Massobrio M, Bellei E, Vinciguerra R, Barbieri A et al. Short-term effects of expiration under positive pressure in patients with acute exacerbation of chronic obstructive pulmonary disease and mild acidosis requiring non-invasive positive pressure ventilation. Intensive Care Medicine 2002;28:581-5. Ref ID: 1342
479. Wollmer P, Ursing K, Midgren B, Eriksson L. Inefficiency of chest percussion in the physical therapy of chronic bronchitis. European Journal of Respiratory Diseases 1985;66:233-9. Ref ID: 1344
480. Brown PM, Manfreda J, McCarthy D, MacDonald S. The effect of mechanical vibration in patients with acute exacerbations of COPD. Physiotherapy Canada 1987;39:371-4. Ref ID: 1497
481. National COPD audit. Royal College of Physicians. 2003. Ref ID: 19461
482. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977;1:1645-8. Ref ID: 19444
483. Harper R. Brazier J E, Waterhouse J C, Walters S J, Jones NMB, Howard P. Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpaitent setting. Thorax 1997;52:879-87. Ref ID: 19445
484. Netten, A. and Curtis, L. Unit Costs of Health and Social Care. 2003. PSSRU. The University of Kent. Ref ID: 19448
485. Guest JF. The annual cost of chronic obstructive pulmonary disease to the UK's National Health Service. Disease Management and Health Outcomes 1999;5:2-100. Ref ID: 19446
486. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000;117:5S-9S. Ref ID: 19338
487. Calverley, P. and Sondhi, S. The burden of obstructive lung disease in the UK - COPD and asthma. Thorax. 1996. Ref ID: 19305
488. The Department of Heath, NHS executive. Burdens of Disease, A discussion document. 1996. London. The Department of Heath. Ref ID: 19344
489. Gibson PG, Wlodarczyk JH, Wilson AJ, Sprogis A. Severe exacerbation of chronic obstructive airways disease: health resource use in general practice and hospital. J Qual Clin Pract 1998;18:125-33. Ref ID: 19318
490. McGuire A, Irwin DE, Fenn P, Gray A, Anderson P, Lovering A et al. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales. Value Health 2001;4:370-5. Ref ID: 19327
491. Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet 2000;355:1931-1935.